Family Management Corp Acquires Shares of 25,374 Hologic, Inc. (NASDAQ:HOLX)

Family Management Corp bought a new stake in Hologic, Inc. (NASDAQ:HOLX) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 25,374 shares of the medical equipment provider’s stock, valued at approximately $1,774,000.

A number of other institutional investors have also recently made changes to their positions in HOLX. Crestline Management LP raised its stake in shares of Hologic by 889.0% during the fourth quarter. Crestline Management LP now owns 53,059 shares of the medical equipment provider’s stock worth $3,825,000 after acquiring an additional 47,694 shares in the last quarter. Centiva Capital LP bought a new stake in Hologic in the fourth quarter worth $1,969,000. Brevan Howard Capital Management LP boosted its position in Hologic by 85.5% during the fourth quarter. Brevan Howard Capital Management LP now owns 19,436 shares of the medical equipment provider’s stock valued at $1,401,000 after buying an additional 8,960 shares during the period. Captrust Financial Advisors grew its stake in shares of Hologic by 22.3% during the fourth quarter. Captrust Financial Advisors now owns 15,410 shares of the medical equipment provider’s stock valued at $1,111,000 after buying an additional 2,812 shares during the last quarter. Finally, Baird Financial Group Inc. increased its stake in Hologic by 2.9% in the 4th quarter. Baird Financial Group Inc. now owns 67,618 shares of the medical equipment provider’s stock worth $4,875,000 after purchasing an additional 1,892 shares during the period. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Stock Up 4.3 %

HOLX opened at $55.41 on Thursday. Hologic, Inc. has a twelve month low of $51.90 and a twelve month high of $84.67. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. The firm has a 50 day moving average price of $59.69 and a 200-day moving average price of $68.69. The stock has a market capitalization of $12.43 billion, a price-to-earnings ratio of 17.48, a PEG ratio of 2.14 and a beta of 0.54.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, beating the consensus estimate of $1.02 by $0.01. The firm had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $1 billion. Hologic had a return on equity of 19.72% and a net margin of 18.42%. The company’s revenue was down 1.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.03 EPS. Equities research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on HOLX. StockNews.com cut shares of Hologic from a “buy” rating to a “hold” rating in a research report on Monday. Raymond James restated an “outperform” rating and set a $71.00 price target (down previously from $90.00) on shares of Hologic in a report on Friday, May 2nd. Royal Bank of Canada reduced their target price on Hologic from $75.00 to $70.00 and set a “sector perform” rating on the stock in a research note on Friday, May 2nd. Needham & Company LLC reissued a “hold” rating on shares of Hologic in a research report on Friday, May 2nd. Finally, Argus cut shares of Hologic from a “buy” rating to a “hold” rating in a research report on Monday, March 3rd. Twelve analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $79.85.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.